> Details

Puttick, Clare; Jones, Thomas P.; Leung, Michelle M.; Galvez-Cancino, Felipe; Liu, Jiali; Varas-Godoy, Manuel; Rowan, Andrew; Pich, Oriol; Martinez-Ruiz, Carlos; Bentham, Robert; Dijkstra, Krijn K.; Black, James R. M.; Rosenthal, Rachel; Kanu, Nnennaya; Litchfield, Kevin; Salgado, Roberto; Moore, David A.; Van Loo, Peter; Jamal-Hanjani, Mariam; Quezada, Sergio A.; Cheyne, Heather; Khalil, Mohammed; Richardson, Shirley; Cruickshank, Tracey; [...]

MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution
  • Contributor: Puttick, Clare; Jones, Thomas P.; Leung, Michelle M.; Galvez-Cancino, Felipe; Liu, Jiali; Varas-Godoy, Manuel; Rowan, Andrew; Pich, Oriol; Martinez-Ruiz, Carlos; Bentham, Robert; Dijkstra, Krijn K.; Black, James R. M.; Rosenthal, Rachel; Kanu, Nnennaya; Litchfield, Kevin; Salgado, Roberto; Moore, David A.; Van Loo, Peter; Jamal-Hanjani, Mariam; Quezada, Sergio A.; Cheyne, Heather; Khalil, Mohammed; Richardson, Shirley; Cruickshank, Tracey; [...]
  • Published: Springer Science and Business Media LLC, 2024
  • Published in: Nature Genetics, 56 (2024) 10, Seite 2121-2131
  • Language: English
  • DOI: 10.1038/s41588-024-01883-8
  • ISSN: 1061-4036; 1546-1718
  • Origination:
  • Footnote:
  • Description: AbstractDisruption of the class I human leukocyte antigen (HLA) molecules has important implications for immune evasion and tumor evolution. We developed major histocompatibility complex loss of heterozygosity (LOH), allele-specific mutation and measurement of expression and repression (MHC Hammer). We identified extensive variability in HLA allelic expression and pervasive HLA alternative splicing in normal lung and breast tissue. In lung TRACERx and lung and breast TCGA cohorts, 61% of lung adenocarcinoma (LUAD), 76% of lung squamous cell carcinoma (LUSC) and 35% of estrogen receptor-positive (ER+) cancers harbored class I HLA transcriptional repression, while HLA tumor-enriched alternative splicing occurred in 31%, 11% and 15% of LUAD, LUSC and ER+ cancers. Consistent with the importance of HLA dysfunction in tumor evolution, in LUADs, HLA LOH was associated with metastasis and LUAD primary tumor regions seeding a metastasis had a lower effective neoantigen burden than non-seeding regions. These data highlight the extent and importance of HLA transcriptomic disruption, including repression and alternative splicing in cancer evolution.